Marvin & Palmer Associates’s Regeneron Pharmaceuticals REGN Stock Holding History

Marvin & Palmer Associates’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-4,255	Closed	-$2.31M	–	57
2015 Q4	$2.31M	Sell	4,255 -150	-3%	-$81.3K	2.37%	20
2015 Q3	$2.05M	Sell	4,405 -1,230	-22%	-$661K	2.45%	19
2015 Q2	$2.88M	Hold	5,635	–	–	2.72%	10
2015 Q1	$2.54M	Buy	5,635 +565	+11%	+$239K	2.2%	18
2014 Q4	$2.08M	Buy	5,070 +1,047	+26%	+$412K	2.11%	20
2014 Q3	$1.45M	Buy	+4,023	New	+$1.35M	1.48%	29
2013 Q3	–	Sell	-10,200	Closed	-$2.29M	–	81
2013 Q2	$2.29M	Buy	+10,200	New	+$2.38M	1.24%	32

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Marvin & Palmer Associates's REGN Position: Q1 2016 in Review

Marvin & Palmer Associates sold out of Regeneron Pharmaceuticals (REGN) in Q1 2016, closing a stake of 4,255 shares — an estimated $2.31M sold.

Marvin & Palmer Associates first reported a position in REGN in Q2 2013 and held it in 7 quarters. The position peaked at $2.88M in Q2 2015. 550 funds tracked by Wall St. Rank hold REGN as of Q1 2016.

Marvin & Palmer Associates reported no remaining Regeneron Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
Marvin & Palmer Associates sold 4,255 Regeneron Pharmaceuticals shares in Q1 2016, an estimated $2.31M.
Marvin & Palmer Associates first reported a position in Regeneron Pharmaceuticals in Q2 2013 and held it in 7 quarters.
Marvin & Palmer Associates's Regeneron Pharmaceuticals position peaked at $2.88M in Q2 2015.
550 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2016.

Based on Marvin & Palmer Associates's 13F filing for Q1 2016, filed 11 May 2016.